title: [Heart transplantation].
abstract: In carefully selected patients with end-stage heart failure heart transplantation has developed from an experimental procedure to standard therapy during the last 30 years. It is currently accepted as a procedure for prolonging life and also for improving quality of life. According to the Registry of the International Society for Heart and Lung Transplantation the overall one-year actuarial survival is 79% and 10-year survival barely 50%. Nine years after the start of the Heart Transplant Program at Rigshospitalet the overall actuarial survival of 157 consecutive patients is 66%. Due to the limited donor access a decline of heart transplant recipients has been recorded during the late nineties. Mechanical replacement of the heart may develop from technological advances and possibly this therapy may gain a complementary status in heart failure, however the human biological replacement is currently the standard.
authors.forename: S A
authors.initials: SA
authors.lastname: Mortensen
authors.forename: S
authors.initials: S
authors.lastname: Boesgaard
authors.forename: H C
authors.initials: HC
authors.lastname: Arendrup
authors.forename: L W
authors.initials: LW
authors.lastname: Andersen
authors.forename: J
authors.initials: J
authors.lastname: Aldershvile
mesh_terms: D000075202:Contraindications; D006084:Graft Rejection / Q000175:diagnosis / Q000517:prevention & control / Q000628:therapy; D016027:Heart Transplantation / Q000379:methods / Q000401:mortality; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D010351:Patient Discharge; D018579:Patient Selection; D011183:Postoperative Complications / Q000175:diagnosis / Q000517:prevention & control / Q000628:therapy; D011379:Prognosis; D011788:Quality of Life; D015996:Survival Rate; D009927:Tissue and Organ Procurement; D014850:Waiting Lists
chemical_list: D007166:Immunosuppressive Agents